Effects of an Antithrombin Drug in Patients with Subacute Exacerbations of Binswanger Disease.

Tomimoto, Hidekazu; Akiguchi, Ichiro; Ohtani, Ryo; Yano, Hideo; Ogura, Satoshi; Wakita, Hideaki

doi:10.2169/internalmedicine.39.966

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed pattern of protection for warfarin users is consistent with evidence for warfarin possibly being protective of cognitive function [13–20]. The protective effect of warfarin on cognition could lend biological plausibly to a lowered risk of motor vehicle crashes attributable to cognitive decline in elderly drivers.…”

Section: Discussionsupporting

confidence: 72%

Warfarin use and the risk of motor vehicle crash in older drivers

Delaney

Opatrny

Suissa

2005

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimOn the basis of a recent report, we assessed whether the use of warfarin by elderly drivers results in an increased risk of motor vehicle crash. MethodsWe used computerized records of Quebec insurance prog rammes, covering a population of 7 million people, to conduct a case-control study based on 5579 cases and 12 911 controls. ResultsThe rate of injurious motor vehicle crash associated with the use of war farin in the past year was not elevated (rate ratio 0.74; 95% confidence interval 0.55, 1.05). ConclusionsWarfarin therapy does not appear to increase the risk of motor vehicle accidents in elderly drivers.

show abstract

Section: Discussionsupporting

confidence: 72%

Warfarin use and the risk of motor vehicle crash in older drivers

Delaney

Opatrny

Suissa

2005

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The group of patients treated with argatroban showed improvements in cognitive function and gait disorder, as compared with patients treated with an antiplatelet drug [80]. …”

Section: Treatment Of Vadmentioning

confidence: 99%

Neuroprotection in Vascular Dementia

et al. 2006

View full text Add to dashboard Cite

Vascular dementia (VaD) is the second most common form of dementia after Alzheimer’s disease (AD), and one of the major causes of mental and physical disability in developed countries. As such, the identification and implementation of strategies which prevent the development of the condition or enable improvements in patients with VaD are healthcare objectives of the first order. VaD is now regarded as a combined group of clinical-pathological entities rather than one disease, that is, multiple pathogenic mechanisms and lesion types underlie a cognitive impairment of vascular origin. The clinical diagnosis of VaD is complex and difficult because of the heterogeneous nature of its clinical presentation and progression and the low sensitivity of existing clinical criteria. Moreover, there is growing evidence of the epidemiological significance of mixed forms of dementia, and that ischemic processes may precipitate and exacerbate cognitive impairment in AD. Numerous compounds have been proposed as potentially useful in the treatment of patients with VaD, comprising vasodilatative, antithrombotic, hemorrheological, nootropic, antiserotoninergic and, most recently, antiglutamatergic and cholinergic approaches. In spite of some initially favorable reports based on the use of memantine, donepezil and galantamine, there is as yet no conclusive evidence of a definitive treatment for VaD. Unsatisfactory results from VaD drug trials may be attributed in part to the diversity of the patients included (underlying pathogenic mechanisms, number, type, and location of vascular lesions), and to methodological limitations in the design of the trials (outcome measures, end-points, size, follow-up period). The treatment of modifiable vascular risk factors – hypertension, diabetes mellitus, hypercholesterolemia and heart disease – is an important strategy for the reduction of the risk of dementia, and is likely to slow the progress of cognitive decline.

show abstract

Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients

Gomez-Puerta¹

2005

Rheumatology

View full text Add to dashboard Cite

show abstract

Effects of an Antithrombin Drug in Patients with Subacute Exacerbations of Binswanger Disease.

Cited by 4 publications

References 25 publications

Warfarin use and the risk of motor vehicle crash in older drivers

Warfarin use and the risk of motor vehicle crash in older drivers

Neuroprotection in Vascular Dementia

Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients

Contact Info

Product

Resources

About